Drug Profile
Olmesartan medoxomil - Daiichi Sankyo Company
Alternative Names: Alteis; Benetor; Benevas; Benicar; Cardosal; CS 866; CS 866RN; CS-866DM; DE-092; Ixia; Mencord; Olmec; Olmes; Olmesartan; Olmetec; Olmighty; Olvance™; Omesar; Openvas; RNH-6270; Tensonit; VotumLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Developer AbbVie; Daewoong Pharmaceutical; Daiichi Sankyo Company; Menarini; Merck & Co; Pfizer; Sun Pharmaceutical Industries
- Class Antihypertensives; Eye disorder therapies; Imidazoles; Small molecules; Tetrazoles
- Mechanism of Action Angiotensin type 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hypertension
- Discontinued Diabetic nephropathies